Evidence map›Paper›PMID 33398533›Full record

ArticleJournal of neuro-oncology2021

Clear cell histology portends a worse prognosis than other WHO grade II histologies.

Pranay Soni, Jianning Shao, Arbaz Momin, Diana Lopez, Lilyana Angelov, Alireza M Mohammadi, Gene H Barnett, Pablo F Recinos, Varun R Kshettry

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Clear cell meningioma: Experience at a medical center.Surgical neurology international · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Pranay SoniDepartment of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Jianning ShaoDepartment of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Arbaz MominDepartment of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Diana LopezDepartment of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Lilyana AngelovDepartment of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Alireza M MohammadiDepartment of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Gene H BarnettDepartment of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Pablo F RecinosDepartment of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Varun R KshettryDepartment of Neurosurgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. kshettv@ccf.org.ORCID http://orcid.org/0000-0003-3217-8279
Cleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeClear cell meningioma (CCM) is a rare WHO grade II meningioma variant, characterized by aggressive features and a high tumor recurrence rate. In this study, we compared overall and progression-free survivals between CCMs and other WHO grade II meningiomas.

methodsA retrospective institutional database review was performed to identify all patients who underwent surgical resection of a WHO grade II meningioma between 1997 and 2019. Overall survival and progression-free survival were compared between patients with clear cell meningiomas and patients with other WHO grade II meningiomas. Multivariable Cox proportional-hazards analysis was used to identify independent predictors of tumor recurrence and survival.

resultsWe included a total of 214 patients in this study (43 CCMs, 171 other WHO grade II meningiomas). Patients with CCMs had significantly shorter progression-free (p = 0.001) and overall (p = 0.026) survivals than patients with other grade II meningiomas. In multivariable analysis, clear cell histology was a significant and powerful independent predictor of tumor recurrence (HR 1.93; 95% CI 1.14-3.26) when controlling for tumor location, extent of resection, and adjuvant radiation. In multivariable analysis, clear cell histology correlated with increased mortality (HR 1.96, 95% CI 0.97-3.94), though this was not statistically significant.

conclusionThis is the first study to compare overall and progression-free survivals between CCMs and other WHO grade II meningiomas. Clear cell histology predicts a higher risk of tumor recurrence and mortality than other grade II histologies. Future studies may help to understand the impact of these findings and the treatment implications.

Indexed as

Combined Modality TherapyDisease ProgressionFemaleFollow-Up StudiesHumansMaleMeningeal NeoplasmsMeningiomaMiddle AgedNeurosurgical ProceduresPrognosisRadiotherapy, AdjuvantRetrospective StudiesSurvival RateWorld Health OrganizationAtypical meningiomaClear cell meningiomaOverall survivalProgression-free survivalWHO grade II meningioma

Identifiers

PMID33398533
OpenAlexW3119585621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.